April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Utility and costs of ophthalmic consultation for fungemia
Author Affiliations & Notes
  • Devon Ghodasra
    Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA
  • Kian Eftekhari
    Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA
  • Ankoor R Shah
    Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA
  • Brian L VanderBeek
    Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA
  • Footnotes
    Commercial Relationships Devon Ghodasra, None; Kian Eftekhari, None; Ankoor Shah, None; Brian VanderBeek, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2850. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Devon Ghodasra, Kian Eftekhari, Ankoor R Shah, Brian L VanderBeek; Utility and costs of ophthalmic consultation for fungemia. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2850.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Currently, ophthalmologic consultation is recommended for all inpatients with fungemia. These patients, however, are often critically ill and have a high mortality rate. In addition, with earlier detection and antifungal use the rate of ocular involvement may be decreasing. The purpose of this study is to determine the utility and associated costs of inpatient ophthalmic consultation for fungemic patients.

Methods: A retrospective case series of all adult patients with positive fungal blood cultures at the Hospital of the University of Pennsylvania from 2008-2012.

Results: 36 of 474 (7.6%) of eyes and 22 of 239 patients (9.2%) had fungal eye involvement. The most common organism identified were Candida albicans (45.6%) and Candida parapsilosis(13.8%).Of these, management was changed in only 9 patients(8 medication changes/1 antifungal intravitreal injection/0 vitrectomies). 39.1% of patients without eye involvement and 31.8% with eye involvement died before discharge or were discharged to hospice.The mortality rate was higher for fungemic patients too sick for eye examination(66/110, 60% vs. 69/239 (28.9%) for those without a consult). The cost of new consults was $91,537 (239 visits at $383/visit). The cost of follow-up visits was $22,880 (130 visits at $176/visit). The total cost per patient who had their management changed was $12,713/patient. Since only 1 patient required an intravitreal injection, the cost to find that one patient was $114,417.

Conclusions: Ocular involvement was present in 9% of patients with fungemia and an even lower incidence of cases in which the ophthalmic examination changed management. These rates are even lower once the high mortality rate is factored in. Our results suggest that routine ophthalmic examination of patients with fungemia without other ocular signs may not be cost-effective.

Keywords: 513 endophthalmitis • 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower • 422 antibiotics/antifungals/antiparasitics  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.